Breast cancer patients exhibit variable responses to neoadjuvant therapy (NAT), necessitating robust predictive biomarkers. We developed an artificial intelligence (AI)-driven integrated predictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results